What Are Prostaglandin Analogs?
Prostaglandin analogs are a class of topical eye medications that lower intraocular pressure (IOP) by increasing uveoscleral outflow, and they represent the first-line medical therapy for glaucoma and ocular hypertension. 1
Mechanism of Action
Prostaglandin analogs work primarily by enhancing uveoscleral outflow of aqueous humor from the eye, which is a different mechanism than other glaucoma medications 2, 3. They achieve this through:
- Regulation of matrix metalloproteinases and remodeling of extracellular matrix in the outflow pathways
- Widening of connective tissue-filled spaces
- Changes in cell shape that alter tissue permeability
- Some evidence suggests they may also slightly increase trabecular outflow facility and stimulate aqueous flow 3
Available Medications
The currently available prostaglandin analogs include 2, 4:
- Latanoprost (most commonly prescribed, best tolerability profile) 5
- Bimatoprost (highest IOP-lowering efficacy) 5
- Travoprost
- Tafluprost
- Unoprostone (less effective, questionable classification as true prostaglandin analog) 6
These medications mimic PGF2α and primarily target the FP prostaglandin receptor 2.
Clinical Efficacy
Prostaglandin analogs reduce IOP by approximately 25-33% and are the most efficacious glaucoma medications available 1, 7. Network meta-analyses consistently demonstrate that bimatoprost, latanoprost, and travoprost rank among the most effective IOP-lowering drugs, though within-class differences are small and may not be clinically meaningful 5.
Why They Are First-Line Therapy
Prostaglandin analogs have become the standard first-line treatment because they offer 1:
- Superior efficacy compared to other medication classes
- Once-daily dosing (improving adherence)
- Excellent systemic tolerability (minimal cardiovascular or pulmonary side effects unlike beta-blockers)
- Better diurnal IOP control
The 2021 AAO Primary Open-Angle Glaucoma Preferred Practice Pattern explicitly states that prostaglandin analogs are often considered as initial medical therapy unless contraindications, cost, side effects, intolerance, or patient refusal preclude this 1.
Important Side Effects
The major ocular adverse effects include:
- Increased iris pigmentation (most common in green-brown eyes, likely permanent due to increased melanin synthesis) 7
- Conjunctival hyperemia (redness)
- Eyelash changes (lengthening, darkening, thickening)
- Periorbital skin pigmentation
- Cystoid macular edema (rare, predominantly in predisposed eyes such as those with prior cataract surgery or uveitis) 7
Clinical Considerations
Patients should be counseled about the permanent iris color change before starting therapy. The systemic safety profile is excellent because plasma concentrations remain below levels needed for FP-receptor stimulation elsewhere in the body 7.
When combined with other glaucoma medications (beta-blockers, alpha-agonists, carbonic anhydrase inhibitors), prostaglandin analogs demonstrate additive IOP-lowering effects 7, 1.